| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | AZ628 | GDSC1000 | pan-cancer | AAC | -0.046 | 0.3 |
| mRNA | ruxolitinib | GDSC1000 | pan-cancer | AAC | 0.032 | 0.3 |
| mRNA | Erlotinib | GDSC1000 | pan-cancer | AAC | 0.046 | 0.3 |
| mRNA | PRL-3 Inhibitor I | CTRPv2 | pan-cancer | AAC | 0.037 | 0.3 |
| mRNA | PHA-665752 | CCLE | pan-cancer | AAC | -0.045 | 0.3 |
| mRNA | BIRB 0796 | FIMM | pan-cancer | AAC | 0.18 | 0.3 |
| mRNA | Bortezomib | gCSI | pan-cancer | AAC | 0.055 | 0.3 |
| mRNA | ciclopirox | CTRPv2 | pan-cancer | AAC | 0.032 | 0.3 |
| mRNA | BRD-K50799972 | CTRPv2 | pan-cancer | AAC | 0.037 | 0.3 |
| mRNA | Bexarotene | CTRPv2 | pan-cancer | AAC | 0.035 | 0.3 |